title: Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis.
abstract: OBJECTIVE
  To evaluate the impact of neoadjuvant hormonal therapy (NHT) on quality of life after external-beam radiotherapy (EBRT) for prostate cancer.
  
  
  METHODS
  A group of 170 patients (85 with and 85 without NHT) has been surveyed prospectively before EBRT (70.2-72 Gy), at the last day of EBRT, a median time of 2 months and 15 months after EBRT using a validated questionnaire (Expanded Prostate Cancer Index Composite). Pairs with and without NHT (median treatment time of 3.5 months before EBRT) were matched according to the respective planning target volume and prostate volume.
  
  
  RESULTS
  Before EBRT, significantly lower urinary function/bother, sexual function and hormonal function/bother scores were found for patients with NHT. More than 1 year after EBRT, only sexual function scores remained lower. In a multivariate analysis, NHT and adjuvant hormonal therapy (HT) versus NHT only (hazard ratio 14; 95% confidence interval 2.7-183; p = 0.02) and luteinizing hormone-releasing hormone (LHRH) agonists versus antiandrogens (hazard ratio 3.6; 95% confidence interval 1.1-12; p = 0.04) proved to be independent risk factors for long-term erectile dysfunction (no or very poor ability to have an erection).
  
  
  CONCLUSIONS
  With the exception of sexual function (additional adjuvant HT and application of LHRH analog independently adverse), short-term NHT was not found to decrease quality of life after EBRT for prostate cancer.
authors.affiliation: Klinik für Strahlentherapie, Universitätsklinikum RWTH Aachen, Pauwelsstrasse 30, 52057 Aachen, Germany. mpinkawa@ukaachen.de
authors.forename: Michael
authors.initials: M
authors.lastname: Pinkawa
authors.forename: Marc D
authors.initials: MD
authors.lastname: Piroth
authors.forename: Branka
authors.initials: B
authors.lastname: Asadpour
authors.forename: Bernd
authors.initials: B
authors.lastname: Gagel
authors.forename: Karin
authors.initials: K
authors.lastname: Fischedick
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Siluschek
authors.forename: Mareike
authors.initials: M
authors.lastname: Kehl
authors.forename: Barbara
authors.initials: B
authors.lastname: Krenkel
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Eble
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D005858:Germany / Q000453:epidemiology; D020249:Hormone Replacement Therapy / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000706:statistics & numerical data; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D011788:Quality of Life; D020266:Radiotherapy, Conformal / Q000706:statistics & numerical data*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome